NASDAQ:CHMA - Chiasma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.84 +0.11 (+2.95 %) (As of 12/12/2018 11:21 AM ET)Previous Close$3.73Today's Range$3.68 - $3.8452-Week Range$1.20 - $4.87Volume7,476 shsAverage Volume61,538 shsMarket Capitalization$86.73 millionP/E RatioN/ADividend YieldN/ABeta1.08 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Waltham, Massachusetts. Receive CHMA News and Ratings via Email Sign-up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHMA Previous Symbol CUSIPN/A Webwww.chiasmapharma.com Phone617-928-5300 Debt Debt-to-Equity RatioN/A Current Ratio5.64 Quick Ratio5.64 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book1.50 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-26,820,000.00 Net MarginsN/A Return on Equity-54.27% Return on Assets-46.88% Miscellaneous Employees16 Outstanding Shares24,430,000Market Cap$86.73 million OptionableNot Optionable Chiasma (NASDAQ:CHMA) Frequently Asked Questions What is Chiasma's stock symbol? Chiasma trades on the NASDAQ under the ticker symbol "CHMA." How were Chiasma's earnings last quarter? Chiasma Inc (NASDAQ:CHMA) issued its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.00. View Chiasma's Earnings History. When is Chiasma's next earnings date? Chiasma is scheduled to release their next quarterly earnings announcement on Tuesday, March 19th 2019. View Earnings Estimates for Chiasma. Has Chiasma been receiving favorable news coverage? Press coverage about CHMA stock has been trending positive on Wednesday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chiasma earned a news impact score of 2.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. Who are some of Chiasma's key competitors? Some companies that are related to Chiasma include American Brivision (Holding) (ABVC), resTORbio (TORC), Aclaris Therapeutics (ACRS), OptiNose (OPTN), Verastem (VSTM), Marker Therapeutics (MRKR), Keryx Biopharmaceuticals (KERX), Stemline Therapeutics (STML), Seres Therapeutics (MCRB), Aratana Therapeutics (PETX), Minerva Neurosciences (NERV), Albireo Pharma (ALBO), Concert Pharmaceuticals (CNCE), Evelo Biosciences (EVLO) and Avid Bioservices (CDMO). Who are Chiasma's key executives? Chiasma's management team includes the folowing people: Mr. Mark J. Fitzpatrick, Pres, CEO, Sec. & Director (Age 55)Mr. Drew Enamait, VP of Fin. & Admin. and Principal Accounting Officer (Age 44)Dr. Gary Patou, Head of Clinical (Age 59)Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 53)Dr. Asi Haviv DMD, VP of Clinical Devel. When did Chiasma IPO? (CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers. Who are Chiasma's major shareholders? Chiasma's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (9.73%), Nexthera Capital LP (2.61%), Point72 Asset Management L.P. (1.64%), EcoR1 Capital LLC (1.55%), Vanguard Group Inc. (1.33%) and Bridgeway Capital Management Inc. (0.95%). Company insiders that own Chiasma stock include Roni Mamluk and Scott Minick. View Institutional Ownership Trends for Chiasma. Which institutional investors are selling Chiasma stock? CHMA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., FMR LLC and Bridgeway Capital Management Inc.. View Insider Buying and Selling for Chiasma. Which institutional investors are buying Chiasma stock? CHMA stock was bought by a variety of institutional investors in the last quarter, including Nexthera Capital LP, EcoR1 Capital LLC, Vanguard Group Inc., Dimensional Fund Advisors LP, Citadel Advisors LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Chiasma. How do I buy shares of Chiasma? Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Chiasma's stock price today? One share of CHMA stock can currently be purchased for approximately $3.84. How big of a company is Chiasma? Chiasma has a market capitalization of $86.73 million. Chiasma employs 16 workers across the globe. What is Chiasma's official website? The official website for Chiasma is http://www.chiasmapharma.com. How can I contact Chiasma? Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected] MarketBeat Community Rating for Chiasma (NASDAQ CHMA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 164 (Vote Outperform)Underperform Votes: 170 (Vote Underperform)Total Votes: 334MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe CHMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHMA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: Do Tariffs Work?